Industry News

Deal Inked for Oral Cancer Vaccine Research

UbiVac and Janssen Biotech will collaborate in preclinical and clinical versions of UbiVac’s proprietary DRibble immunotherapy for use in preclinical studies of oral.

Read More
WordPress Ads